Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ramatroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 18/20 | 1.00 |
| ▸ | TBXA2R known ✓ | P21731 | 8/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RB1 | P06400 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ramatroban SCHEMBL29030 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL20769768 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL29503087 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL1427851 | 1.00 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL1427848 | 0.99 | PTGDR2 (0.98) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL1427850 | 0.99 | PTGDR2 (0.98) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL9442771 | 0.95 | PTGDR2 (0.90) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL9833660 | 0.93 | PTGDR2 (0.87) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL1427849 | 0.92 | PTGDR2 (0.85) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL9429657 | 0.92 | PTGDR2 (0.85) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3515 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-17 | — | — | US | claimed |
| CN-120154601-A | Application of ramatrum Ban Zaizhi in preparation of medicine for preventing or treating radioactive esophageal injury caused by ionizing radiation | 核工业四一六医院 | 2025-06-17 | — | — | CN | claimed |
| US-20250144079-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2025-05-08 | — | — | US | claimed |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-01-21 | — | — | US | claimed |
| CN-112368300-B | SPNS2 neutralizing antibodies | 帝人制药株式会社 | 2024-10-01 | — | — | CN | claimed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | claimed |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-06 | — | — | US | claimed |
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| CN-117122687-A | Methods for inhibiting tumor metastasis | 凡德贝尔大学 | 2023-11-28 | — | — | CN | claimed |
| CN-1282320-A | Thermodynamically stable form of -3- [ [ (4-fluorophenyl) sulfonyl ] amino ] -1, 2,3, 4-tetrahydro-9H-carbazole-9-propanoic acid (ramatroban) | BAYER YAKUHIN LTD (JP) | 2001-01-31 | — | — | CN | claimed |
| EP-1051398-A1 | THERMODYNAMICALLY STABLE FORM OF (R)-3- (4-FLUOROPHENYL) SULPHONYL]AMINO] -1,2,3,4- TETRAHYDRO -9H-CARBAZOLE -9-PROPANOIC ACID (RAMATROBAN) | BAYER YAKUHIN LTD. (JP) | 2000-11-15 | — | — | EP | claimed |
| WO-1999033803-A1 | THERMODYNAMICALLY STABLE FORM OF (R)-3-[ [(4-FLUOROPHENYL) SULPHONYL]AMINO] -1,2,3,4- TETRAHYDRO -9H-CARBAZOLE -9-PROPANOIC ACID (RAMATROBAN) | BAYER YAKUHIN, LTD. (JP) | 1999-07-08 | — | — | WO | claimed |
| US-5462726-A | Suppressing vasoconstriction | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-31 | — | — | US | claimed |
| US-5204121-A | Active material core, double layer comprising outer acrylic layer and inner jacket of hydrophobic additive and hydroxy-propyl cellulose | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-20 | — | — | US | claimed |
| EP-0386440-B1 | MEDICAMENT WITH CONTROLLED RELEASE OF THE ACTIVE INGREDIENT | BAYER AG (DE) | 1992-08-05 | — | — | EP | claimed |
| EP-0448274-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions | E.R. SQUIBB & SONS, INC. (US) | 1991-09-25 | — | — | EP | claimed |
| EP-0242518-B1 | Cycloalkano[1,2-b]indole-sulfonamides | BAYER AG (DE) | 1991-04-10 | — | — | EP | claimed |
| US-4965258-A | Anticoagulant; thromboxane a2 antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-23 | — | — | US | claimed |
| EP-0242518-A1 | Cycloalkano[1,2-b]indole-sulfonamides | BAYER AG (DE) | 1987-10-28 | — | — | EP | claimed |